Generic Name and Formulations:
Doripenem (as monohydrate) 250mg/vial, 500mg/vial; pwd for IV infusion after constitution and dilution; preservative-free.
Indications for DORIBAX:
Susceptible complicated intra-abdominal and complicated urinary tract infections (including pyelonephritis).
Give by IV infusion over 1hr; may switch to oral antibiotics after 3 days. ≥18yrs (CrCl >50mL/min): Intra-abdominal: 500mg every 8hrs for 5–14 days. UTI, pyelonephritis: 500mg every 8hrs for 10–14 days. CrCl 30–50mL/min: 250mg every 8hrs; CrCl>10–<30mL/min: 250mg every 12hrs.
<18yrs: not established.
Not for treatment of ventilator-associated bacterial pneumonia. Carbapenems, cephalosporins, penicillins or other allergy. Discontinue if serious hypersensitivity reactions occur and treat. Increased risk of seizures with history of CNS disorders (eg, stroke), renal dysfunction, or doses >500mg every 8hrs. Risk of pneumonitis with inhalational use; avoid this route. Renal impairment; monitor. Pregnancy (Cat.B). Nursing mothers.
Antagonizes valproic acid; if needed, monitor and consider supplemental anticonvulsant. Potentiated by probenecid: not recommended.
Headache, nausea, diarrhea (may be serious; evaluate if occurs), rash, phlebitis, anemia, elevated hepatic enzymes; C. difficile-associated diarrhea, hypersensitivity reactions, seizures.
Single-use vials—1, 10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|